Diana R. Langworthy

Diana R. Langworthy

Auto-generated profile, based on publicly available information

Diana R. Langworthy

University of Minnesota College of Pharmacy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
DLDiana R. Langworthy
Diana R. Langworthy
ASAnne Schullo-Feulner
Anne Schullo-Feulner
EGErica Gannon
Erica Gannon
AFAndrew Fijalka
Andrew Fijalka
CCChristine Czycalla
Christine Czycalla
SSSurbhi Shah
Surbhi Shah

27 September 2022 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
DBDavid Bunch
David Bunch
CBCarolyn Brands
Carolyn Brands
DLDiana R. Langworthy
Diana R. Langworthy
Purpose: A case of sulfamethoxazole/trimethoprim-induced agranulocytosis is reported. Summary: A 53-year-old healthy male presented to the emergency room with a fever of 102.7°F and was found to have a white blood cell (WBC) count of 0.6 × 103 cells/μL with an absolute neutrophil count (ANC) of 0.0 x 103 cells/μL. He had recently completed a 10-day course of sulfamethoxazole/trimethoprim for left lower extremity cellulitis. During admission, a bone marrow biopsy was performed which was not concerning for malignancy and no cause for the agranulocytosis other than the sulfamethoxazole/trimethoprim was identified. The agranulocytosis resolved after 6 days of hospitalization with a WBC count of 8.9 × 103 cells/μL and an ANC of 4.1 x 103cells/μL on the day of discharge. Conclusion: A 53-year-old male developed agranulocytosis after 10 days of sulfamethoxazole/trimethoprim therapy for the treatment of a skin and soft tissue infection. His neutropenia resolved after sulfamethoxazole/trimethoprim discontinuation.

13 September 2024 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
GSGagandeep Singh
Gagandeep Singh
CCCaitlin Canton
Caitlin Canton
DLDiana R. Langworthy
Diana R. Langworthy

20 March 2025 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
DLDiana R. Langworthy
Diana R. Langworthy
JRJennifer K. Ross
Jennifer K. Ross
Introduction: Roux-en-Y gastric bypass (RYGB) is a surgical weight-loss procedure that combines gastric restriction with malabsorption for weight reduction. There is currently a paucity of data to guide pharmacists and healthcare providers in optimizing oral medication therapy in patients with a history of bariatric surgery. Fluconazole is a commonly used triazole antifungal with high oral bioavailability. The literature is limited regarding how RYGB affects oral fluconazole absorption. Case: We investigated fluconazole oral bioavailability in a patient with a history of RYGB status-post revision with esophagojejunal anastomosis. The patient had been maintained on combination therapy with intravenous (IV) micafungin and oral fluconazole due to persistent candidemia prior to source control and concerns regarding fluconazole absorption. On admission, the patient was switched to IV fluconazole in the setting of possible small bowel obstruction. Steady-state fluconazole trough levels obtained during IV and oral therapy were 41.9 μg/mL and 44.4 μg/mL, respectively. Conclusion: We were able to demonstrate oral fluconazole maintains high bioavailability in a patient with RYGB. Fluconazole displays linear pharmacokinetics, therefore the degree of oral absorption reduction would directly correspond to a decreased trough level. Pharmacists and providers should continue to be vigilant when evaluating drug efficacy in patients who have undergone gastric bypass procedures, especially those with malabsorptive mechanisms.